POET: Prevention Of Endometrial Tumours

ISRCTN	ISRCTN22037489
DOI	https://doi.org/10.1186/ISRCTN22037489
EudraCT/CTIS number	2006-001815-30
ClinicalTrials.gov number	NCT00566644
Secondary identifying numbers	N/A

Submission date: 08/01/2007
Registration date: 21/02/2007
Last edited: 04/06/2015

Recruitment status: Stopped
Overall study status: Stopped
Condition category: Cancer

Prospectively registered

Protocol

Statistical analysis plan

Results

Individual participant data

Record updated in last year

Plain English summary of protocol

http://www.cancerhelp.org.uk/trials/a-trial-looking-at-a-way-of-preventing-cancer-of-the-womb-lining

Study website

Contact information

Prof Shirley V Hodgson
Scientific

Department of Clinical Development Science
Cranmer Terrace
London
SW17 0RE
United Kingdom

Study information

Study design	Randomised controlled trial
Primary study design	Interventional
Secondary study design	Randomised controlled trial
Study setting(s)	Not specified
Study type	Prevention
Scientific title	POET: Prevention Of Endometrial Tumours
Study acronym	POET
Study objectives	POET is an interventional, open, randomised controlled trial looking at the efficacy of the Mirena Intrauterine System (IUS) with surveillance, versus surveillance alone, in reducing the development of Atypical Endometrial Hyperplasia (AEH) and carcinoma in women aged 35 to 65 years with Hereditary Non-Polyposis Colorectal Cancer (HNPCC or Lynch Syndrome). This cohort of women has been selected based on age (35 to 65 years) for inclusion into the study because the risk of Endometrium Cancer (EC) in Lynch syndrome rises from the age of 35 years. This is when surveillance is recommended to start, according to current guidelines. The risk of EC continues to rise post-menopausally so the prophylactic effects of the Mirena IUS could be more significant in this age group.
Ethics approval(s)	Wandsworth REC, 12/04/2005, ref: 05/Q0803/59
Health condition(s) or problem(s) studied	Atypical Endometrial Hyperplasia (AEH) and carcinoma
Intervention	Women will be randomised to receive either Mirena IUS for four years with surveillance (surveillance being annual TransVaginal Sonography [TVS] and Endometrial Biopsies [EB] by pipelle [or hysteroscopy], to document AEH and carcinoma; pathology confirmed) or surveillance only. On 17/06/2009 this record was updated to indicate that this trial was closed prematurely due to poor recruitment.
Intervention type	Device
Pharmaceutical study type(s)
Phase
Drug / device / biological / vaccine name(s)
Primary outcome measure	AEH or EC, during the active follow-up period of the trial
Secondary outcome measures	To address the following questions: 1. What is the age-related incidence of AEH and EC in women with Lynch syndrome? 2. What is the sensitivity and specificity of surveillance with TVS and EB to detect AEH and carcinoma in women with Lynch syndrome? 3. What is the premalignant pathway to carcinoma in women with Lynch syndrome? 4. Does the Mirena IUS reduce the rate of therapeutic hysterectomy for AEH or cancer in women with Lynch syndrome? 5. Are there psychological benefits or adverse effects from the use of the Mirena IUS? 6. What is the satisfaction and compliance with screening? 7. What is the extent of adverse effects of surveillance and use of the Mirena IUS? (subsequent investigation of abnormalities detected on surveillance or side-effects of the Mirena) 8. In the longer term, with separate funding, we will determine the molecular changes associated with pre-malignant changes in the endometrium in women with Lynch syndrome, and possibly the utility of tests on cervical mucus samples to diagnose endometrial neoplasia.
Overall study start date	15/01/2007
Completion date	31/01/2013
Reason abandoned (if study stopped)	Lack of participants

Eligibility

Participant type(s)	Patient
Age group	Adult
Lower age limit	18 Years
Sex	Female
Target number of participants	220
Key inclusion criteria	Women aged 35 to 65 years are eligible if: 1. Proven to carry a pathogenic germline mutation in a DNA mismatch repair gene causing Lynch syndrome (usually MSH2, MLH1, MSH6) 2. Women: a. from a family fulfilling the Amsterdam or the modified Amsterdam criteria for Lynch syndrome (three relatives with an Lynch syndrome-related cancer (colorectal, small bowel, endometrial, ovarian, urothelial or hepatobiliary), one the first-degree relative of the other two, two generations affected, and one diagnosis before the age of 50 years) AND b. who themselves have had colorectal cancer, a large, villous or severely dysplastic colorectal adenoma before the age of 40 years, or small bowel, hepatobiliary, or urothelial cancer, and where abnormal immunohistochemistry staining for Lynch syndrome proteins in the tumour has been demonstrated in an affected family member. The aim is to randomise 220 women within 18 months of opening the trial. However, randomising as many as 800 women could be justified in order to evaluate the effect of Mirena separately pre- and post-menopause. 3. Risk equivalent A patient may be randomised in the POET trial if it can be proved that she is a carrier. For example, this could be due to the woman being an obligate carrier in a family meeting the Amsterdam Criteria and including other evidence of a mis-match repair defect. Having a risk equivalent entry point will also allow for someone who was only a second degree relative of an affected family member, but who herself had had bowel cancer at age 35, for instance, to be eligible in the trial. Eligibility will be confirmed in writing by Prof. Hodgson, Dr Sheridan or Dr Murday and a copy of the email/letter will be kept with the patients notes for monitoring purposes.
Key exclusion criteria	1. Women without an intact uterus (or who are planning a prophylactic hysterectomy) 2. Known or suspected pregnancy 3. Women trying to become pregnant in the next three years 4. Infected abortion during the three months before Mirena insertion is planned 5. Concomitant use of intrauterine devices 6. History of, or active, genital malignancy or breast carcinoma or other oestrogen dependent tumours 7. Any kind of active malignancy 8. Currently on therapy for cancer 9. Pelvic inflammatory disease (PID) during previous 6 months (before the Mirena IUS insertion) or recurrent PID 10. Clinically significant submucous myomas requiring treatment. Small subserous or intramural myomas, clinically assessed as insignificant, are acceptable 11. Any known hypersensitivity to the constituents of the Mirena IUS 12. An unresolved abnormal cervical smear 13. Trophoblastic disease while hCG levels remain elevated 14. Any clinically significant condition or laboratory result that might, in the opinion of the investigator, compromise patient safety, interfere with the evaluations or prevent the completion of the trial 15. Outside the age-range for the study 16. Current or previous severe arterial disease (Stroke, M1) or severe liver disease
Date of first enrolment	11/07/2007
Date of final enrolment	31/03/2009

Locations

Countries of recruitment

England
United Kingdom

Study participating centre

St George's, University of London

London
SW17 0RE
United Kingdom

Sponsor information

St George's, University of London & Queen Mary and Westfield College, University of London (UK)
University/education

R & D, Floor 3
Rutland House
42-46 New Road
Whitechapel
London
E1 2AX
England
United Kingdom

"ROR"	https://ror.org/026zzn846

Funders

Funder type

Charity

Cancer Research UK (CRUK) (UK)
Private sector organisation / Other non-profit organizations

Alternative name(s): CR_UK, Cancer Research UK - London, CRUK
Location: United Kingdom

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to share	No
IPD sharing plan summary	Not provided at time of registration
Publication and dissemination plan	Not provided at time of registration
IPD sharing plan